1. Home
  2. AKRO vs CPA Comparison

AKRO vs CPA Comparison

Compare AKRO & CPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • CPA
  • Stock Information
  • Founded
  • AKRO 2017
  • CPA 1947
  • Country
  • AKRO United States
  • CPA Panama
  • Employees
  • AKRO N/A
  • CPA N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • CPA Air Freight/Delivery Services
  • Sector
  • AKRO Health Care
  • CPA Consumer Discretionary
  • Exchange
  • AKRO Nasdaq
  • CPA Nasdaq
  • Market Cap
  • AKRO 3.9B
  • CPA 4.4B
  • IPO Year
  • AKRO 2019
  • CPA 2005
  • Fundamental
  • Price
  • AKRO $54.20
  • CPA $102.48
  • Analyst Decision
  • AKRO Strong Buy
  • CPA Strong Buy
  • Analyst Count
  • AKRO 6
  • CPA 5
  • Target Price
  • AKRO $82.50
  • CPA $153.00
  • AVG Volume (30 Days)
  • AKRO 1.8M
  • CPA 410.5K
  • Earning Date
  • AKRO 08-08-2025
  • CPA 08-06-2025
  • Dividend Yield
  • AKRO N/A
  • CPA 6.28%
  • EPS Growth
  • AKRO N/A
  • CPA 5.12
  • EPS
  • AKRO N/A
  • CPA 14.63
  • Revenue
  • AKRO N/A
  • CPA $3,451,912,000.00
  • Revenue This Year
  • AKRO N/A
  • CPA $5.54
  • Revenue Next Year
  • AKRO N/A
  • CPA $9.27
  • P/E Ratio
  • AKRO N/A
  • CPA $7.09
  • Revenue Growth
  • AKRO N/A
  • CPA N/A
  • 52 Week Low
  • AKRO $21.02
  • CPA $80.01
  • 52 Week High
  • AKRO $58.40
  • CPA $110.73
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 62.96
  • CPA 46.11
  • Support Level
  • AKRO $53.61
  • CPA $102.00
  • Resistance Level
  • AKRO $56.49
  • CPA $106.75
  • Average True Range (ATR)
  • AKRO 2.40
  • CPA 2.74
  • MACD
  • AKRO -0.08
  • CPA -1.04
  • Stochastic Oscillator
  • AKRO 65.93
  • CPA 5.50

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About CPA Copa Holdings S.A.

Copa Holdings SA is a provider of airline passenger and cargo services through its subsidiaries. The company operates through the air transportation segment. It offers international air transportation for passengers, cargo, and mail, operating from its Panama City hub in the Republic of Panama, and domestic and international air transportation for passengers, cargo, and mail with a point-to-point route network through Copa Colombia, a Colombian air carrier. The company's geographical segments are North America, South America, Central America, and the Caribbean. It derives the maximum revenue from North America.

Share on Social Networks: